Recent Posts
- INTERACT vs Pre-IND Meeting: Which FDA Meeting to Request
- Fast Track vs. Breakthrough Therapy Designation: Understanding the Key Differences
- Understanding FDA Review Structure: Why Your Audience Matters in Regulatory Strategy
- Orphan Drug Designation by the European Medicines Agency (EMA ODD)
- Expedited Programs Beyond Orphan Designation
Recent Comments
No comments to show.
Category Archives: Blog
The Benefits of Orphan Drug Designation and Market Exclusivity
Orphan Drug Designation (ODD) is one of the earliest and most essential regulatory steps for sponsors developing therapies for rare diseases. For eligible products, this designation opens the door to significant financial, regulatory, and strategic advantages that can shape the … Continue reading
Posted in Blog
Comments Off on The Benefits of Orphan Drug Designation and Market Exclusivity
FDA Introduces Rare Disease Evidence Principles (RDEP) to Advance Orphan Drug Development
The FDA’s New Rare Disease Evidence Principles The U.S. Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP), a new framework designed to provide greater clarity and predictability for drug developers pursuing therapies for rare diseases. … Continue reading
Posted in Blog
Comments Off on FDA Introduces Rare Disease Evidence Principles (RDEP) to Advance Orphan Drug Development